Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 23, 2022 11:30 ET | Cytokinetics, Incorporated
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Analyses from...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 18, 2022 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
May 17, 2022 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
May 17, 2022 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 16, 2022 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Hold Annual Meeting of Stockholders
May 03, 2022 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Tuesday, May 10, 2022...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Announce First Quarter Results on May 4, 2022
April 20, 2022 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
April 03, 2022 09:45 ET | Cytokinetics, Incorporated
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from...
Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
April 02, 2022 11:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of...